The future of focal therapy

Two “pro” and “con” commentaries appeared on line this week in the Journal of Urology under the heading “Focal therapy will become standard treatment for localized prostate cancer.” .. READ MORE …

How many current, PSA-detected, localized prostate cancers are really appropriate for focal therapy?

It is well understood that current Western screening and diagnostic processes commonly identify patients with low volume, low Gleason grade prostate cancer tumors (e.g., a single biopsy core with < 10 percent of the core  positive for cancer of Gleason score 3 + 3 = 6). … READ MORE …

The potential of focal therapy: another assessment

For several years, various research teams have been assessing the potential of focal therapy as a means to treat carefully selected men with localized prostate cancer. However, to date, the ability to identify such men with accuracy prior to such treatment is still in question. … READ MORE …

Focal (hemiablative) HIFU in the treatment of localized prostate cancer

To date there have been few data from well-documented, prospective series of patients receiving any form of focal therapy as treatment for localized prostate cancer, and the criteria for the appropriate clinical use of focal therapy are still a matter of considerable debate. … READ MORE …

Clinical “success” and the management of low-risk, localized prostate cancer

Historically, “success” in the treatment of localized prostate cancer was the elimination of all evidence of cancer from the patient’s prostate and other nearby tissues — through radical surgery or radiation therapy of some type. But the increasing acceptance of active surveillance and the evolution of focal forms of therapy have introduced whole new ways of thinking about the “successful” management of low- and even intermediate-risk, localized disease. … READ MORE …

The natural history of low-risk prostate cancer

In a presentation given at the annual meeting of the American Urology Association earlier this year, researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) provided some interesting data on the natural history of prostate cancer in patients initially diagnosed with low-risk disease. … READ MORE …

If you decide to donate your body for prostate cancer research …

… after you pass away, this is the sort of study that you may be able to watch it be used for (always assuming that there is actually a life after death and that you have the ability to observe what happens to your prior “vessel”). … READ MORE …

Prostate cancer news reports: Tuesday, April 20, 2010

In today’s news reports we note new articles dealing with:

  • Biopsy protocols, patient selection, and focal therapy
  • Tertiary Gleason pattern 4/5 and risk for progression post-RP
  • Evolving data on the uses of bisphosphonates and denosumab
  • SKIs in treatment of advanced forms of prostate cancer … READ MORE …

Prostate cancer news reports: Sunday, November 8, 2009

This weekend’s news report includes items on:

  • Numbers of biopsy cores and accuracy of diagnosis for focal therapy
  • Early data from the Prostate Cancer Research International: Active Surveillance (PRIAS) study
  • Ultrasensitive PSA testing and risk of progression following radical prostatectomy … READ MORE …

The focal therapy discussion continues

An article in this week’s New England Journal of Medicine has argued that an earlier report, postulating the monoclonal origin of lethal metastatic prostate cancer, increases the justification for focal therapy for early stage prostate cancer. … READ MORE …

Prostate cancer news reports: Tuesday, June 9, 2009

Today’s news reports deal with items on:

  • The mechanism of action of D,L-sulforaphane
  • Isolation of an active protein from the bitter melon plant
  • The potential of focal therapy for localized prostate cancer
  • Reconstruction of the lower urinary tract after radical prostatectomy
  • Hypofractionated intensity-modulated arc radiotherapy in  N1 prostate cancer … READ MORE …

Cryotherapy for localized prostate cancer today: a cryotherapist’s opinion

Dr. Aaron Katz has been practicing cryotherapy at Columbia University Medical Center in New York since 1993, so one could reasonably expect him to have a sophisticated appreciation for the pros and cons of this technique. … READ MORE …

Prostate cancer news reports: Tuesday, May 19, 2009

Today’s reports address:

  • How German prostate cancer specialists would treat themselves
  • Identification of patients appropriate for focal therapy
  • Italian management of men with an elevated PSA level
  • Triple therapy for men with T3a,b disease … READ MORE …

Prostate cancer news reports: Saturday, May 16, 2009

Today’s news reports cover such matters as:

  • Genistein as a prostate cancer stimulating agent
  • Molecular characterization of advanced prostate cancers
  • Imaging technology and focal therapy … READ MORE …

The news report: Friday, April 24, 2009

In today’s news report we touch on papers that address:

  • Genome studies and identification of real genomic risk for prostate cancer
  • More on the potential of 5-ARIs in prevention of prostate cancer
  • Whether we really need more studies on selenium as a potential prostate cancer prevention agent
  • The evolving potential of targeted focal therapy … READ MORE …